brexucabtagene autoleucel
AXP000015.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- Kite Pharma
- Sponsor
- Kite Pharma (Gilead Sciences)
Names
| Name | Type | Source |
|---|---|---|
| brexucabtagene autoleucel | preferred name, INN | curator, ncit |
| Tecartus | brand | ncit |
| KTE-X19 | code | ncit |
| brexu-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- retrovirus
- Replication
- non replicating
- Modifications
- replication-incompetent retroviral vector; murine anti-CD19 scFv linked to CD28 and CD3 zeta domains
- Transgenes
- anti-CD19 chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C170439
- Wikidata
- Q97704053
- FDA UNII
- 4MD2J2T8SJ
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2020-07-24 | approved | Tecartus | Adults with relapsed or refractory mantle cell lymphoma, and adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | source |
| EMA | EU | 2020-12-14 | conditional | Tecartus | Adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a BTK inhibitor; adults aged 26 and over with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | source |
Clinical trials (21)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy | Recruiting | Phase 2 | 2026-11-01 | 2028-05-01 | 26 | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma |
| NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Recruiting | Phase 2 | 2026-09-25 | 2028-03-01 | 59 | Non-hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma |
| NCT07673367 | Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Recruiting | Phase 2 | 2026-07-31 | 2031-07-31 | 25 | Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma |
| NCT06553872 | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Recruiting | Phase 2 | 2024-08-23 | 2029-08 | 60 | Mantle Cell Lymphoma |
| NCT06287229 | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Recruiting | Phase 1/2 | 2024-07-11 | 2028-12-31 | 40 | B-cell Acute Lymphocytic Leukemia; Relapsed/Refractory |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | Recruiting | Phase 2 | 2024-05-07 | 2027-07-31 | 40 | B Cell Lymphoma |
| NCT06253663 | Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Active not recruiting | Phase 2 | 2024-03-18 | 2027-07 | 25 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory Mantle Cell Lymphoma |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma | Recruiting | Phase 2 | 2024-02-15 | 2031-06-15 | 150 | Mantle Cell Lymphoma |
| NCT06144606 | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | Phase 2 | 2023-12-26 | 2031-07-29 | 60 | Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia |
| NCT05993949 | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | Active not recruiting | Phase 1 | 2023-10-02 | 2025-07-17 | 8 | Lymphoblastic Leukemia |
| NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Active not recruiting | Early phase 1 | 2022-11-18 | 2027-03-31 | 22 | Lymphoma; Mantle Cell Lymphoma |
| NCT05537766 | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Terminated | Phase 2 | 2022-11-01 | 2025-01-27 | 19 | Relapsed/Refractory Burkitt Lymphoma; Relapsed/Refractory Hairy Cell Leukemia; Relapsed/Refractory Richter Transformation; Relapsed/Refractory Waldenstrom Macroglobulinemia |
| NCT05041309 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | Enrolling by invitation | 2021-12-15 | 2040-12 | 1500 | Autoimmune Diseases; Solid and Hematological Malignancies | |
| NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Completed | Phase 2 | 2021-04-23 | 2025-06-17 | 95 | Relapsed/Refractory Mantle Cell Lymphoma |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active not recruiting | Phase 2 | 2018-12-18 | 2024-02-09 | 150 | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
| NCT03624036 | Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Terminated | Phase 1 | 2018-11-15 | 2021-02-12 | 16 | Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma |
| NCT02614066 | A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | Completed | Phase 1/2 | 2016-03-07 | 2022-07-23 | 125 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia |
| NCT02625480 | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Completed | Phase 1/2 | 2016-02-01 | 2026-03-25 | 95 | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | Completed | Phase 2 | 2015-11-09 | 2023-09-22 | 105 | Relapsed/Refractory Mantle Cell Lymphoma |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | Available | Acute Lymphoblastic Leukemia; Mantle Cell Lymphoma | ||||
| NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies | Approved for marketing | Relapse/Refractory Mantle Cell Lymphoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41052404 | CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. | Blood advances | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41160777 | Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3. | Blood | 2026 | cited by trial NCT02601313 |
| PMID 41311365 | Managing Treatment-Emergent Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CAR-T Cell Therapy: A Case-Based Review of the use of Emapalumab. | Hematological oncology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41487336 | Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy. | Journal of medical cases | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41568643 | [Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia]. | Recenti progressi in medicina | 2026 | name in title: brexu-cel |
| PMID 41568644 | [Case of brexu-cel at first relapse in an elderly patient]. | Recenti progressi in medicina | 2026 | name in title: brexu-cel |
| PMID 41568646 | [A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage]. | Recenti progressi in medicina | 2026 | name in title: brexu-cel |
| PMID 41568647 | [To transplant or not to transplant after CAR-T: that is the question!]. | Recenti progressi in medicina | 2026 | name in abstract: brexu-cel |
| PMID 41686452 | Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. | Blood advances | 2026 | cited by trial NCT02601313 |
| PMID 41779968 | Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT. | Blood advances | 2026 | name in title: brexu-cel |
| PMID 41796018 | Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival. | British journal of haematology | 2026 | name in title: brexucabtagene autoleucel |
| PMID 41972172 | Case Report: Durable remission of intraocular mantle cell lymphoma after CD19 CAR-T therapy. | Frontiers in immunology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42036693 | Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. | Journal of hematology & oncology | 2026 | cited by trial NCT02601313 |
| PMID 42147078 | CAR T-cell therapy-associated central hypothyroidism: a case of a novel onco-endocrine toxicity. | JCEM case reports | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42178058 | Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies. | Transplantation and cellular therapy | 2026 | name in abstract: brexu-cel |
| PMID 42285114 | Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study. | The Lancet. Haematology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42364734 | Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia. | Transplantation and cellular therapy | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42564502 | Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report. | Therapeutic advances in medical oncology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42581349 | Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance. | BMC cancer | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42988007 | Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. | Transplantation and cellular therapy | 2026 | cited by trial NCT02614066 |
| PMID 39152952 | Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid. | Cytotherapy | 2025 | name in title: brexucabtagene autoleucel |
| PMID 39418622 | Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: brexucabtagene autoleucel |
| PMID 39710966 | Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study. | British journal of haematology | 2025 | name in title: brexucabtagene autoleucel |
| PMID 39718764 | Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B-ALL Relapse. | American journal of hematology | 2025 | name in title: brexucabtagene autoleucel |
| PMID 39833958 | Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report. | Journal of medical case reports | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39866330 | Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy. | ACG case reports journal | 2025 | name in abstract: Tecartus |
| PMID 40084458 | [Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report]. | Recenti progressi in medicina | 2025 | name in abstract: brexu-cel |
| PMID 40084459 | [Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case]. | Recenti progressi in medicina | 2025 | name in title: brexucabtagene autoleucel |
| PMID 40084460 | [CAR-T cell therapy in a patient with relapsed/refractory mantle cell lymphoma]. | Recenti progressi in medicina | 2025 | name in abstract: KTE-X19 |
| PMID 40090005 | Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. | Blood | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40203192 | Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study. | Blood advances | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40209059 | ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia. | Blood | 2025 | cited by trial NCT03624036 |
| PMID 40255392 | Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. | Frontiers in immunology | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40334068 | Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. | Blood advances | 2025 | name in title: brexucabtagene autoleucel |
| PMID 40517546 | First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. | Hematological oncology | 2025 | cited by trial NCT06482684 |
| PMID 40989690 | Posterior reversible encephalopathy syndrome after CD19 chimeric antigen receptor therapy for B-acute lymphoblastic leukemia: case report. | Frontiers in oncology | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 41671463 | Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT06287229 |
| PMID 37605437 | Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. | European journal of haematology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38248629 | Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. | Leukemia & lymphoma | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38552193 | Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38644613 | CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation. | European journal of haematology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38703571 | Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report. | International immunopharmacology | 2024 | name in abstract: Tecartus |
| PMID 39093952 | Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. | Blood advances | 2024 | name in title: brexucabtagene autoleucel |
| PMID 39328803 | Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia. | Journal of medical cases | 2024 | name in title: brexucabtagene autoleucel |
| PMID 39474550 | Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma. | Case reports in oncology | 2024 | name in title: brexucabtagene autoleucel |
| PMID 35635259 | Use of long-term corticosteroids in patients treated with CAR T-cell therapy. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 35658525 | Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT02601313 |
| PMID 36263840 | Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. | Haematologica | 2023 | cited by trial NCT02625480 |
| PMID 36660565 | Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease. | Radiology case reports | 2023 | name in title: brexucabtagene autoleucel |
| PMID 37584447 | The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. | American journal of hematology | 2023 | name in title: brexucabtagene autoleucel |
| PMID 35727476 | Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. | Advances in therapy | 2022 | cited by trial NCT02614066 |
| PMID 35983953 | FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. | The oncologist | 2022 | name in title: brexucabtagene autoleucel |
| PMID 36494725 | Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. | Journal of hematology & oncology | 2022 | cited by trial NCT02614066 |
| PMID 33152104 | Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. | British journal of haematology | 2021 | name in title: brexucabtagene autoleucel |
| PMID 33827116 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. | Blood | 2021 | cited by trial NCT02614066 |
| PMID 34097852 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. | Lancet (London, England) | 2021 | cited by trial NCT02614066 |
| PMID 32242358 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. | The New England journal of medicine | 2020 | cited by trial NCT02601313 |
| PMID 33067318 | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. | Journal for immunotherapy of cancer | 2020 | cited by trial NCT02601313 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41026973 | Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. | Blood advances | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41207679 | T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions. | European journal of haematology | 2026 | name in abstract: brexu-cel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41448297 | Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis. | Critical reviews in oncology/hematology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41545665 | Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland. | Bone marrow transplantation | 2026 | name in title: brexucabtagene autoleucel |
| PMID 41546434 | Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome. | Journal of neuroimaging : official journal of the American Society of Neuroimaging | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41643192 | Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. | Blood | 2026 | name in title: brexucabtagene autoleucel |
| PMID 41676895 | ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study. | Haematologica | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 41686453 | Brute force: the effects of ibrutinib on brexu-cel. | Blood advances | 2026 | name in title: brexu-cel |
| PMID 41964291 | Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response. | Transfusion | 2026 | name in abstract: brexu-cel |
| PMID 42002230 | Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42077190 | Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. | American journal of hematology | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42099215 | Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study. | Technology in cancer research & treatment | 2026 | name in title: Tecartus |
| PMID 42137294 | Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies. | Molecular therapy. Advances | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42242518 | Brexucabtagene Autoleucel in the Outpatient Setting: A Single-Institution Experience. | Transplantation and cellular therapy | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42289300 | Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma. | British journal of haematology | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42297689 | Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status. | Endocrinologia, diabetes y nutricion | 2026 | name in abstract: brexu-cel |
| PMID 42319489 | Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation. | Annals of hematology | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42329247 | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42349018 | Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. | Blood advances | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42449653 | Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma. | Cancers | 2026 | name in abstract: brexu-cel |
| PMID 42471153 | Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42482164 | Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel. | Clinical pharmacology and therapeutics | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42537846 | Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data. | Transplantation and cellular therapy | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42753811 | B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42808549 | Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis. | Journal of managed care & specialty pharmacy | 2026 | name in title: brexucabtagene autoleucel |
| PMID 42844744 | Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42844780 | CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital. | Acta clinica Belgica | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42863677 | Impact of Prophylactic Steroids on Chimeric Antigen Receptor T-Cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42908664 | Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database. | Frontiers in pharmacology | 2026 | name in abstract: Tecartus |
| PMID 42919964 | Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma. | Nature medicine | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 42945698 | The summa of ZUMA: Lessons from a decade of CD19-targeted CAR-T trials in B-cell malignancies. | Leukemia research | 2026 | name in abstract: brexucabtagene autoleucel |
| PMID 39316713 | The present and future of CAR T-cell therapy for adult B-cell ALL. | Blood | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39368017 | Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. | PharmacoEconomics | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39418599 | Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. | Blood advances | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39562721 | Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. | Leukemia | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39779930 | T cell malignancies after CAR T cell therapy in the DESCAR-T registry. | Nature medicine | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39791458 | Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. | Leukemia & lymphoma | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 39913291 | Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. | Blood cancer discovery | 2025 | name in title: brexucabtagene autoleucel |
| PMID 39972592 | Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patterns. | British journal of haematology | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40108332 | Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. | Leukemia | 2025 | name in title: brexucabtagene autoleucel |
| PMID 40127395 | Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. | Blood advances | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40146949 | Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network. | Neurology | 2025 | name in abstract: brexu-cel |
| PMID 40346502 | Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. | BMC cancer | 2025 | name in abstract: brexu-cel |
| PMID 40485666 | Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies. | Therapeutic advances in drug safety | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40520784 | Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece. | Frontiers in medicine | 2025 | name in abstract: brexu-cel |
| PMID 40665156 | [CAR T cell therapy in acute lymphoblastic leukemia]. | Innere Medizin (Heidelberg, Germany) | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40689917 | Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase. | Therapeutic innovation & regulatory science | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40706035 | Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. | Blood advances | 2025 | name in title: brexucabtagene autoleucel |
| PMID 40726603 | Low Occurrence of Ocular Adverse Events after CAR-T Cell Therapy. | Ocular oncology and pathology | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 40754556 | Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024). | Discover oncology | 2025 | name in abstract: brexu-cel |
| PMID 40833241 | Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma. | American journal of hematology | 2025 | name in title: brexucabtagene autoleucel |
| PMID 40849364 | The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. | Bone marrow transplantation | 2025 | name in title: brexucabtagene autoleucel |
| PMID 41090103 | Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions. | Oncoscience | 2025 | name in abstract: brexu-cel |
| PMID 41201546 | Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy. | Current hematologic malignancy reports | 2025 | name in abstract: brexucabtagene autoleucel |
| PMID 37840282 | Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. | Leukemia & lymphoma | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38105391 | Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia. | European journal of haematology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38166723 | Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database. | BMC cancer | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38295285 | Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. | Blood advances | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38326887 | The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. | Experimental hematology & oncology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38350684 | Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy. | Journal for immunotherapy of cancer | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38437908 | Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults. | Critical reviews in oncology/hematology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38473919 | Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR). | International journal of molecular sciences | 2024 | name in abstract: brexu-cel |
| PMID 38494076 | Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. | Transplantation and cellular therapy | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38494543 | Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. | Advances in therapy | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38498731 | CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. | Blood advances | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38544797 | Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. | EClinicalMedicine | 2024 | name in abstract: brexu-cel |
| PMID 38641057 | Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38667277 | Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes. | Cells | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38785408 | Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials. | Leukemia & lymphoma | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38817691 | The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going? | Clinical hematology international | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38873532 | Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis. | HemaSphere | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38899352 | Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. | Haematologica | 2024 | name in title: brexucabtagene autoleucel |
| PMID 38926998 | [Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma--Review]. | Zhongguo shi yan xue ye xue za zhi | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 38975903 | Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis. | Leukemia & lymphoma | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 39034731 | FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges. | Current pharmaceutical biotechnology | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 39200107 | Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment. | Biomedicines | 2024 | name in abstract: brexu-cel |
| PMID 39201242 | A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications. | International journal of molecular sciences | 2024 | name in abstract: brexu-cel |
| PMID 39207868 | Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry. | Blood advances | 2024 | name in title: brexucabtagene autoleucel |
| PMID 39234101 | CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023). | Frontiers in pharmacology | 2024 | name in abstract: brexu-cel |
| PMID 39310608 | Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead. | Cureus | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 39413830 | The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. | Journal of the National Comprehensive Cancer Network : JNCCN | 2024 | name in abstract: brexucabtagene autoleucel |
| PMID 39559248 | Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. | Cancer management and research | 2024 | name in title: brexucabtagene autoleucel |
| PMID 39632795 | Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review. | Expert review of pharmacoeconomics & outcomes research | 2024 | name in title: brexu-cel |
| PMID 36585394 | Top advances of the year: Leukemia. | Cancer | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 36732205 | Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. | Blood reviews | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 36753699 | Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | name in title: brexucabtagene autoleucel |
| PMID 36867678 | CD19 CAR antigen engagement mechanisms and affinity tuning. | Science immunology | 2023 | name in abstract: Tecartus |
| PMID 37004047 | CAR T-Cell therapy for the management of mantle cell lymphoma. | Molecular cancer | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 37188352 | Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer? | British journal of haematology | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 37229538 | Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma. | Leukemia & lymphoma | 2023 | name in title: brexucabtagene autoleucel |
| PMID 37288738 | Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update. | Expert review of pharmacoeconomics & outcomes research | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 37339099 | In brief: Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukemia. | The Medical letter on drugs and therapeutics | 2023 | name in title: brexucabtagene autoleucel |
| PMID 37518011 | Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. | Journal of translational medicine | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 37536448 | Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects. | Critical reviews in oncology/hematology | 2023 | name in abstract: brexucabtagene autoleucel |
| PMID 37626659 | A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database. | Biomedicines | 2023 | name in abstract: brexu-cel |
| PMID 37648261 | Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. | Journal for immunotherapy of cancer | 2023 | name in title: brexucabtagene autoleucel |
| PMID 37654738 | Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma. | HemaSphere | 2023 | name in title: brexucabtagene autoleucel |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA309280 | Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumors | CHILDREN'S HOSP OF PHILADELPHIA | MA, LEYUAN | 2026–2026 | name in abstract: Tecartus |
| UG1HL069286 | BMT CTN Core- University of Pennsylvania Abramson Cancer Center | UNIVERSITY OF PENNSYLVANIA | STADTMAUER, EDWARD A | 2024–2026 | name in abstract: brexu-cel |
| UG1HL109137 | Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell Therapies | WASHINGTON UNIVERSITY | PUSIC, ISKRA | 2024–2026 | name in abstract: brexucabtagene autoleucel |
Notes
Same CAR construct as axi-cel but T-cell-enriched manufacturing; separate INN, so separate program.
How to cite
brexucabtagene autoleucel (AXP000015.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000015.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.